Metabolomics approach using HR-MAS NMR spectroscopy for the assessment of metabolic profiles of uterine fibroids
Analytical Biochemistry · 2025
DOI: 10.1016/j.ab.2025.115885 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Biochemistry, 2025. Verfasst von Senem Arda Düz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Reproductive Sciences & Advanced Bioinformatics Application & Research Center, Inonu University, Malatya, Türkiye; Department of Obstetrics and Gynec…. Hauptthemen laut MEDLINE: Leiomyoma, Metabolomics, Metabolome, Uterine Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Inönü Üniversitesi.
Abstract (Originalsprache)
The aim of this study is to determine dysregulated metabolites and metabolic pathways in uterine fibroids and in the myometrial tissue from which uterine fibroids are derived. Fifteen (15) patients underwent hysterectomy because of uterine fibroids and 14 controls were included in this study. 1H HR-MAS NMR spectroscopy data were obtained from uterine fibroid tissue, the adjacent healthy myometrial tissue from cases, and myometrial tissue from controls. PCA and PLS-DA score plots from multivariate statistical analysis of pre-processed spectral data demonstrated a distinction between cases and control groups. The levels of lactate, alanine, glutamate, glutamine, methionine, acetone, isocitrate, choline, glycerophosphocholine, phosphocholine, o-phosphoethanolamine, taurine, myo-inositol, p-methylhistidine, phenylacetate, ascorbate, glucose, and methylhistidine were significantly higher in uterine fibroid tissue compared to the neighboring healthy myometrial tissue. Additionally, when adjacent healthy myometrial tissue was compared to control myometrial tissue, significantly lower levels of valine, leucine, isoleucine, ethanol, arginine, N-acetyl tyrosine, acetone, p-methylhistidine, glucose, phenylacetate, myo-inositol, and alpha-glucose were observed. The study provides a foundational framework by revealing the metabolomic heterogeneity of uterine fibroids. Strategies should be developed to target the metabolic alterations that contribute to the growth of these common tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Reproductive Sciences & Advanced Bioinformatics Application & Research Center, Inonu University, Malatya, Türkiye; Department of Obstetrics and Gynecology, Inonu University, School of Medicine, Malatya, Türkiye.
- Reproductive Sciences & Advanced Bioinformatics Application & Research Center, Inonu University, Malatya, Türkiye; Laboratory of NMR, Scientific and Technological Research Center, Inonu University, Malatya, Türkiye.
- Reproductive Sciences & Advanced Bioinformatics Application & Research Center, Inonu University, Malatya, Türkiye; Department of Biomedical Engineering, Faculty of Engineering, Inonu University, Malatya, Türkiye.
- Reproductive Sciences & Advanced Bioinformatics Application & Research Center, Inonu University, Malatya, Türkiye; Department of Obstetrics and Gynecology, Inonu University, School of Medicine, Malatya, Türkiye. Electro…
Förderung
- Inönü Üniversitesi
Zitieren
APA
Düz, S. A., Mumcu, A., Doğan, B., Sarıdoğan, E., Tuncay, G., Onat, T., & Karaer, A. (2025). Metabolomics approach using HR-MAS NMR spectroscopy for the assessment of metabolic profiles of uterine fibroids. Analytical Biochemistry. https://doi.org/10.1016/j.ab.2025.115885
Vancouver
Düz SA, Mumcu A, Doğan B, Sarıdoğan E, Tuncay G, Onat T, et al. Metabolomics approach using HR-MAS NMR spectroscopy for the assessment of metabolic profiles of uterine fibroids. Analytical Biochemistry. 2025. doi:10.1016/j.ab.2025.115885
BibTeX
@article{Dz2025,
author = {Düz, Senem Arda and Mumcu, Akın and Doğan, Berat and Sarıdoğan, Erdinç and Tuncay, Görkem and Onat, Taylan and Karaer, Abdullah},
title = {Metabolomics approach using HR-MAS NMR spectroscopy for the assessment of metabolic profiles of uterine fibroids},
journal = {Analytical Biochemistry},
year = {2025},
doi = {10.1016/j.ab.2025.115885}
}
EUVIMED